Written by the Nuvirox Research Team
KEY POINTS
- In mice, NAD+ precursors improve insulin sensitivity and metabolic markers impressively.
- In the key human trial, NR raised NAD+ but did not improve insulin sensitivity or body composition.
- The honest read: promising biology, disappointing human metabolic outcomes so far.
Short answer: great in mice, unconvincing in people so far. NAD+ precursors have produced striking metabolic benefits in rodent studies — better insulin sensitivity, protection against diet-induced obesity — which is why "NAD+ for metabolism" became a story. But the most relevant human trial raised NAD+ and failed to move insulin sensitivity or body composition. That gap between species is the part you need to know.
Why does NAD+ get linked to metabolism?
NAD+ is fundamental to energy metabolism: it's the coenzyme that helps convert nutrients into ATP and shuttles electrons during the reactions that extract energy from food. It also activates sirtuins, enzymes involved in metabolic regulation. On paper, more NAD+ should mean smoother metabolic machinery — and in animals, that paper logic often holds up.
In mice, the NAD+ precursor NR enhanced oxidative metabolism and protected against high-fat-diet-induced obesity. Results like that are genuinely impressive — and genuinely in mice.
What happened when researchers tested people?
The translation has been humbling. The standout human metabolic trial is worth stating plainly.
STUDY SNAPSHOT
| Design | Randomized, placebo-controlled |
| Population | Obese men |
| Dose / duration | NR, 12 weeks |
| NAD+ effect | Raised NAD+ metabolites |
| Metabolic effect | No improvement in insulin sensitivity or body composition |
In obese men, twelve weeks of NR raised NAD+ metabolites but produced no improvement in insulin sensitivity or body composition. The biomarker moved exactly as expected; the metabolic outcomes the study was designed to detect did not. This is the single most important fact in the "NAD+ for metabolism" conversation, and it rarely makes it into the marketing.
There are softer positive signals elsewhere. A nicotinamide-plus-ribose combination modestly lowered blood glucose over seven days in middle-aged adults without changing insulin secretion — a small, short pilot. And NMN trials in older adults have shown NAD+ rises with occasional nominal functional changes. But none of this adds up to a robust demonstration that NAD+ precursors meaningfully improve metabolic health in humans.
How to read the mouse-human gap
It's a recurring theme in this field, not a quirk of one study. Mice are often studied young, inbred, and on extreme diets, with NAD+ pathways that respond more dramatically than ours. Impressive rodent metabolic data should be treated as a reason to run human trials — not as a human result. The careful reading of roughly two dozen human NR trials is that NAD+ elevation is reliable while many downstream benefit claims, including metabolic ones, remain unproven.
What NAD+ won't do for your metabolism
It won't substitute for the interventions with real metabolic evidence — weight management, physical activity, and dietary quality — and it isn't a treatment for insulin resistance, prediabetes, or type 2 diabetes. If you have metabolic concerns or abnormal blood sugar, that's a medical conversation, not a supplement decision. NAD+ may support cellular energy metabolism in a general structure-function sense; it is not a glucose-lowering therapy.
For the related question of whether NAD+ helps with fat loss specifically, our piece on NAD+ supplements and weight loss covers the (similarly modest) evidence.
The trials that didn't deliver — and why that matters
Metabolism is the area where NAD+ precursors have most clearly under-delivered relative to the preclinical hype, and that's worth stating plainly. Dollerup's randomized trial in obese, insulin-resistant men raised NAD+ but found no improvement in insulin sensitivity, hepatic fat, or body composition. The NADPARK and related work moved biomarkers without translating into the dramatic metabolic rescues that rodent studies had suggested. When the animal data look spectacular and the human data look flat, the human data are the ones to trust.
Where a small signal might exist
This isn't a total void. Some work combining nicotinamide-family compounds with other agents has reported modest glucose-related shifts, and certain subgroups (older, more metabolically stressed) may respond differently than healthy young adults. But “modest, inconsistent, subgroup-dependent” is the accurate description, not “metabolic transformation.” If your goal is metabolic health, the interventions with overwhelming evidence — weight management, resistance and aerobic exercise, sleep, and diet quality — dwarf anything an NAD+ precursor has shown.
If you have a diagnosed metabolic condition, this is squarely a clinician's domain rather than a supplement decision — NAD+ precursors are not a treatment for insulin resistance, prediabetes, or type 2 diabetes, and shouldn't be used in place of evidence-based care. The trials simply don't support that use, and the stakes are too high to substitute a supplement for medical management.
The broader lesson from the metabolism data applies across this whole category: impressive mouse results earn a hypothesis, not a conclusion, and the human trials are where that hypothesis goes to be tested honestly. On metabolism, it has mostly come back modest or null.
Frequently asked questions
Does NAD+ improve metabolism in humans?
The strongest human trial raised NAD+ but didn't improve insulin sensitivity or body composition. Impressive metabolic effects exist mainly in mice, not yet in people.
Can NAD+ lower blood sugar?
One small short pilot of a nicotinamide-ribose combination modestly lowered glucose, but this is weak, preliminary evidence — not a basis for using NAD+ to manage blood sugar.
Why does it work in mice but not people?
Rodent studies often use young animals on extreme diets with more responsive NAD+ pathways. Dramatic mouse results frequently don't translate to humans.
Is NAD+ a treatment for insulin resistance?
No. There's no robust human evidence for that, and metabolic conditions need medical management. NAD+ is not a substitute for diet, activity, or medical care.
From Nuvirox
Why we formulated NAD+ Restore
NAD+ Restore is built around 500 mg of Nicotinamide Riboside Chloride (NR) per two-capsule serving — one of the two most-researched NAD+ precursors, within the dose range used in published human trials. We pair it with 150 mg trans-resveratrol (from Japanese Knotweed) and 50 mg quercetin (from Sophora japonica), polyphenols studied alongside NAD+ pathways for cellular health support, plus 10 mg galactomannans from fenugreek to support absorption.
It ships with a 60-day money-back guarantee — long enough to actually evaluate it the way the research says you should.
Learn more about NAD+ Restore →The bottom line
The metabolic case for NAD+ is a cautionary tale about extrapolating from animals. Mouse data is exciting; the key human trial raised NAD+ and changed nothing metabolic. Until better human trials say otherwise, treat NAD+ as general cellular-energy support — not as a tool for blood sugar, insulin sensitivity, or metabolic disease, all of which belong to proven interventions and your doctor.
References
- Dollerup OL, et al. A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects. Am J Clin Nutr. 2018;108(2):343–353. DOI: 10.1093/ajcn/nqy132.
- Xue Y, et al. A combination of nicotinamide and D-ribose (RiaGev) is safe and effective to increase NAD+ metabolome in healthy middle-aged adults: a randomized, triple-blind, placebo-controlled, crossover pilot clinical trial. Nutrients. 2022;14(11):2219. PMC: PMC9183138. DOI: 10.3390/nu14112219.
- Igarashi M, et al. Chronic nicotinamide mononucleotide supplementation elevates blood NAD+ levels and alters muscle function in healthy older men. npj Aging. 2022;8:5. DOI: 10.1038/s41514-022-00084-z.
- Sharma A, et al. What is really known about the effects of nicotinamide riboside supplementation in humans. Sci Adv. (review of 25 human NR trials). DOI: 10.1126/sciadv.adi4862.
- Conze D, Brenner C, Kruger CL. Safety and metabolism of long-term administration of NIAGEN (nicotinamide riboside chloride) in a randomized, double-blind, placebo-controlled clinical trial of healthy overweight adults. Sci Rep. 2019;9:9772. PMC: PMC6611812. DOI: 10.1038/s41598-019-46120-z.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not a substitute for professional medical advice.